Imagine facing a diagnosis of advanced cancer or a chronic condition with limited options—then learning that breakthrough therapies from China are now reaching international markets, offering potentially more effective, accessible treatments. This is the reality unfolding in 2026, as Chinese biopharma accelerates from domestic innovation to global impact.

The wave of innovative drug approvals in China, coupled with major out-licensing deals, signals that high-quality, cutting-edge medicines are no longer confined to one region. Patients everywhere stand to benefit from therapies targeting tough diseases like oncology, autoimmune conditions, and metabolic disorders.

Recent highlights include a landmark exclusive licensing agreement announced on January 12, 2026, between AbbVie and RemeGen for RC148, a novel PD-1/VEGF bispecific antibody. This investigational therapy aims to enhance immune responses against tumors while addressing resistance mechanisms, showing promise in advanced solid tumors including certain lung cancers. Such developments underscore the growing global interest in China's next-generation biologics.

Other trending areas driving this momentum include:

• PD-1/VEGF bispecific antibodies – Emerging as potential challengers to established standards, with strong clinical data in lung and other cancers.
• Antibody-Drug Conjugates (ADCs) – Explosive progress, expanding into earlier treatment lines.
• GLP-1 related innovations – Continuing to transform obesity and metabolic health management.

These trends reflect China's shift toward first-in-class (FIC) and best-in-class (BIC) medicines, fueled by robust pipelines and strategic global collaborations.

Key Chinese Innovative Therapies Gaining Global Attention

Here are some standout examples of Chinese-developed or China-originated innovative drugs making waves internationally:

• RC148 (RemeGen, licensed to AbbVie) → Novel PD-1/VEGF bispecific antibody for advanced solid tumors (e.g., lung cancers), representing a new class to overcome resistance and potentially combine with ADCs.
• SSGJ-707 / PF-08634404 (3SBio, licensed to Pfizer) → Next-generation PD-1/VEGF bispecific antibody advancing to Phase III trials globally, with impressive early efficacy in non-small cell lung cancer.
• Ivonescimab → A PD-1/VEGF dual antibody already approved in China, demonstrating strong potential in thoracic cancers.
• Various ADCs and bispecifics from companies like Hengrui, Innovent, and others → Licensed overseas in record deals, targeting oncology and beyond.

These therapies are not just numbers on a list—they represent renewed possibilities for patients who have exhausted standard options.

At Hong Kong DengYue Medicine, our true value lies in the pursuit of excellence and innovation, while prioritizing sustainability and social responsibility. Built on a foundation of quality, compliance, and integrity, we actively participate in the global market to help bring these promising Chinese-developed therapies to patients worldwide. By facilitating reliable access to specialty and rare drugs—through licensed import/export channels, temperature-controlled logistics, and strict regulatory adherence—we contribute to healthier communities everywhere.

This is more than business; it's about ensuring that breakthroughs from dedicated Chinese innovators reach those who need them most, regardless of borders.

As this exciting chapter continues into 2026 and beyond, we remain optimistic: Chinese innovative medicines are poised to make a lasting difference in global health. For patients and families, that means more options, more hope, and brighter futures.

Stay connected for updates on these evolving trends—because every advancement brings us closer to better care for all.